With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the ...

Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report) today and set a price ...

Fall means it’s time for just about everybody to get up to date on their flu and COVID-19 vaccines – and a lot of older ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior ...

Current health news highlights WeightWatchers offering a compound version of Novo Nordisk's obesity drug, Danco seeking FDA ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

(NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held in Los Angeles ...

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.